The value of decreased plasma gelsolin levels in patients with systemic lupus erythematosus and rheumatoid arthritis in diagnosis and disease activity evaluation

Lupus

Volumn 22, Issue 14, 2013, Pages 1455-1461

  Hu, Y L ^a,b   Li, H ^a,b   Li, W H ^a,b   Meng, H X ^a   Fan, Y Z ^a,b   Li, W J ^a,b   Ji, Y T ^a,b   Zhao, H ^a,b   Zhang, L ^a   Jin, X M ^a   Zhang, F M ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Immunity and Infection Key Laboratory of Heilongjiang Province   (China)

Author keywords

disease activity; Gelsolin; rheumatoid arthritis; systemic lupus erythematosus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GELSOLIN; HEMOGLOBIN; NITROGEN; RHEUMATOID FACTOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DAS28; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; HEMATURIA; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NITROGEN URINE LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RHEUMATOID ARTHRITIS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

DISEASE ACTIVITY; GELSOLIN; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CASE-CONTROL STUDIES; FEMALE; GELSOLIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84887873383     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313507985     Document Type: Article

References (38)

1. Chang X, Zhao Y, Yan X, et al. Investigating a pathogenic role for TXNDC5 in rheumatoid arthritis. Arthritis Res Ther. 2011 ; 13: 124-124
2. Pablos-Álvarez JL. Pathogenic basis of B cell targeted therapy in systemic lupus erythematosus (SLE). Rheumatol Clin. 2010 ; 6S2: 21-24
3. Colglazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: A practical review. South Med J. 2005 ; 98: 185-191
4. Sjöwall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2004 ; 6: 87-94
5. Kasapçopur O, Altun S, Aslan M, et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2004 ; 63: 1687-1689
6. Qiao H, Koya RC, Nakagawa K, et al. Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging. 2005 ; 26: 849-855
7. Tanaka H, Shirkoohi R, Nakagawa K, et al. siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer. 2006 ; 118: 1680-1691
8. Cho JE, Park Wi, Kim DC, et al. Down-regulation of gelsolin may play a role in the progression of inverted papilloma through an antiapoptotic mechanism. Am J Rhinol Allergy. 2012 ; 26 (3). 177-182
9. Litwin M, Nowak D, Mazur AJ, et al. Gelsolin affects the migratory ability of human colon adenocarcinoma and melanoma cells. Life Sci. 2012 ; 90 (21-22). 851-861
10. Shao F, Zhang R, Don L, Ying K. Overexpression of gelsolin-like actin-capping protein is associated with progression of lung adenocarcinoma. Tohoku J Exp Med. 2011 ; 225 (2). 95-101
11. An JH, Kim JW, Jang SM, et al. Gelsolin negatively regulates the activity of tumor suppressor p53 through their physical interaction in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun. 2011 ; 412 (1). 44-49
12. Oikonomou N, Thanasopoulou A, Tzouvelekis A, et al. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. Thorax. 2009 ; 64: 467-475
13. Juusela P, Tanskanen M, Nieminen A, et al. Hereditary gelsolin amyloidosis mimicking Sjögren's syndrome. Clin Rheumatol. 2009 ; 8: 1351-1354
14. Mateos J, Lourido L, Fernández-Puente P, et al. Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF. J Proteomics. 2012 ; 75 (10). 2869-2878
15. DiNubile MJ. Plasma gelsolin as a biomarker of inflammation. Arthritis Res Ther. 2008 ; 10: 124-124
16. Osborn TM, Verdrengh M, Stossel TP, Tarkowski A, Bokarewa M. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res Ther. 2008 ; 10: 117-117
17. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol. 2000 ; 27: 377-379
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
19. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
20. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001 ; 358: 903-911
21. Hoffman IE, Peene I, Meheus L. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis. 2004 ; 63: 1155-1158
22. Li H, Song W, Li Y, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity. Clin Rheumatol. 2010 ; 29: 413-417
23. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci. 2004 ; 61: 2614-2623
24. Philchenkov AA. Caspases as regulators of apoptosis and other cell functions. Biochemistry. 2003 ; 68: 365-376
25. Peng KW, Liou YM. Differential role of actin-binding proteins in controlling the adipogenic differentiation of human CD105-positive Wharton's Jelly cells. Biochim Biophys Acta. 2012 ; 1820 (4). 469-481
26. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat. 2001 ; 65: 11221-11221
27. Pan S, Chen R, Brand RE, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res. 2012 ; 11 (3). 1937-1948
28. Lin CP, Chen YW, Liu WH, et al. Proteomic identification of plasma biomarkers in uterine leiomyoma. Mol Biosyst. 2012 ; 8 (4). 1136-1145
29. Tsai MH, Wu CC, Peng PH, et al. Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. J Mol Med (Berl). 2012 ; 90 (2). 187-200
30. Jin S, Shen JN, Peng JQ, Wang J, Huang G, Li MT. Increased expression of serum gelsolin in patients with osteosarcoma. Chin Med J (Engl). 2012 ; 125: 262-269
31. Chou SH, Lee PS, Konigsberg RG, et al. Plasma-type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke. 2011 ; 42 (12). 3624-3627
32. Xu JF, Liu WG, Dong XQ, Yang SB, Fan J. Change in plasma gelsolin level after traumatic brain injury. J Trauma Acute Care Surg. 2012 ; 72 (2). 491-496
33. Cohen TS, Bucki R, Byfield FJ, et al. Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine. 2011 ; 54 (3). 235-238
34. Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg. 2006 ; 243 (3). 399-403
35. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock and myonecrosis. Crit Care Med. 1997 ; 25: 594-598
36. Rothenbach PA, Dahl B, Schwartz JJ, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol. 2004 ; 96: 25-31
37. Biswas S, Sharma S, Saroha A, et al. Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. PLoS One. 2013 ; 8 (2). e56246 - e56246
38. Guo F, Shen EY, Yu Z, Zhou M. Gelsolin binding agent compositions and uses of same. Patent No. US 8,367,356 B2 2013-02-05.